Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Hemodialysis II: Procedure and Complications

Hemodialysis II: Procedure and Complications

DialyzersA hemodialysis (HD) dialyzer is a plastic cartridge containing thousands of parallel hollow fibers, which serve as semipermeable membranes. These fibers are typically made from cellulose-based or other synthetic materials. During HD, blood is pumped into the top of the cartridge and distributed among these fibers. Simultaneously, dialysis fluid, known as dialysate, is introduced into the bottom of the cartridge, bathing the outside of the fibers. Across the semipermeable membrane,...

Chronic Kidney Disease IV: Nursing Management

Chronic Kidney Disease IV: Nursing Management

Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of fluid...

Hemodialysis III: Nursing Management

Hemodialysis III: Nursing Management

The nursing management of a patient undergoing hemodialysis includes several critical steps, starting with a thorough assessment before the procedure.Before the Hemodialysis ProcedureFirst, record the patient's vital signs—blood pressure, heart rate, respiratory rate, and temperature—to establish a baseline. This baseline is essential for detecting conditions such as hypotension that could impact the patient's response to dialysis. Document the patient's pre-dialysis weight, as this measurement...

Drug Dosage Regimen: Overview

Drug Dosage Regimen: Overview

A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...

Hemodialysis I: Introduction

Hemodialysis I: Introduction

Hemodialysis (HD) is a medical treatment that artificially removes waste products, excess fluids, and toxins from the blood when the kidneys are no longer able to perform these functions effectively. In this process, blood is filtered through a semipermeable membrane, allowing for the selective removal of waste while preserving necessary components like blood cells and proteins. Hemodialysis is typically performed in patients with end-stage renal disease (ESRD) or severe kidney...

Renal Failure: Dose Adjustments

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

TGF-β-specific T cells are frequent in peripheral blood and bone-marrow from patients with myeloproliferative neoplasms.

Leukemia·2025

Same author

Conflating polycythemia vera with essential thrombocytosis.

Blood advances·2025

Same author

Myeloproliferative Neoplasms: Challenging Dogma.

Journal of clinical medicine·2024

Same author

Combination therapy with ruxolitinib and pegylated interferon alfa-2a in newly diagnosed patients with polycythemia vera.

Blood advances·2024

Same author

Recombinant Interferon-β in the Treatment of Polycythemia Vera and Related Neoplasms: Rationales and Perspectives.

Cancers·2022

Same author

Coronary artery- and aortic valve calcifications in patients with Philadelphia-negative myeloproliferative neoplasms.

International journal of cardiology·2022

Search research articles

Related Experiment Video

Updated: Jun 3, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

Hydroxycarbamide: a user's guide for chronic myeloproliferative disorders.

Jerry L Spivak¹, Hans Hasselbalch

¹Traylor 924 Johns Hopkins University School of Medicine, 720 Rutland Avenue, Baltimore, MD 21205, USA. jlspivak@jhmi.edu

Expert Review of Anticancer Therapy

|March 23, 2011

Summary

Hydroxycarbamide effectively treats various conditions by inhibiting DNA synthesis and acting as a nitric oxide donor. Its use in chronic myeloproliferative disorders is beneficial, though leukemic transformation remains debated.

Related Experiment Videos

Last Updated: Jun 3, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

Area of Science:

Pharmacology and Medical Chemistry
Oncology
Hematology

Background:

Hydroxycarbamide is a long-established antiproliferative and antiviral agent.
It is utilized for neoplastic and non-neoplastic conditions, including chronic myeloproliferative disorders.

Purpose of the Study:

To review the pharmacokinetics, pharmacodynamics, clinical applications, and tolerability of hydroxycarbamide.
To discuss its mutagenic potential and toxicity profile, particularly in chronic myeloproliferative disorders.

Main Methods:

Literature search of the Medline database.
Synthesis of existing data on hydroxycarbamide's properties and clinical use.

Main Results:

Hydroxycarbamide inhibits DNA synthesis and acts as a nitric oxide donor, aiding in conditions like thrombocytosis.
Its absorption, distribution, mechanism of action, and side-effect profile are well-documented.
The potential for leukemic transformation with hydroxycarbamide monotherapy is a subject of ongoing controversy.

Conclusions:

Hydroxycarbamide is a valuable therapeutic agent with a defined mechanism and side-effect profile.
Clinicians must weigh the benefits against potential risks, including debated mutagenicity, when using hydroxycarbamide.